Drug Profile
Research programme: arthritis therapy - Galapagos/ZoBio/Pyxis Discovery/Leiden University
Alternative Names: Arthritis therapy research programme - Galapagos, ZoBio, Pyxis Discovery, Leiden UniversityLatest Information Update: 24 May 2010
Price :
$50
*
At a glance
- Originator Galapagos NV; Leiden University; Pyxis Discovery; ZoBio
- Developer Galapagos NV; Pyxis Discovery; ZoBio
- Class Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Rheumatic disorders
Most Recent Events
- 24 May 2010 Discontinued - Preclinical for Rheumatic disorders in Netherlands (unspecified route)
- 12 Aug 2005 Preclinical trials in Rheumatic disorders in Netherlands (unspecified route)